Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

Clarity Pharmaceuticals ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of ...

EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services ConferenceCompany to Present and Host 1x1 Investor Meetings on ...

Recognising these subtle body changes can lead to an earlier diagnosis, when treatment is more likely to be successful ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring ...

The authors have declared no conflicts of interest. The patient provided informed consent for the publication of this case report. Acknowledgements: Gupta was involved in writing the original draft, ...

According to a company press release, RadNet, Inc. has acquired Gleamer SAS, a leading radiology AI company based in Paris, France. The acquisition will be integrated into DeepHealth, RadNet’s wholly ...

The integration of genomic testing into cancer screening enables diagnostics to break away from conventional, one-size-fits-all protocols.